Expertise in
3
conditions

Yang R. Liang

State Key Laboratory Of Oncology In South China, 
Guangzhou, CN 
Expertise in
3
conditions
State Key Laboratory Of Oncology In South China, 
Guangzhou, CN 

Overview

Yang Liang practices practicing medicine in Guangzhou, China.

Mr. Liang is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Leukemia, Multiple Myeloma, Acute Myeloid Leukemia (AML), and Chronic Lymphocytic Leukemia (CLL).

He is actively involved in clinical research, co-authoring 111 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

State Key Laboratory Of Oncology In South China, Guangzhou, 510060, China
Other Locations
Shenzhen, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2

110 Total Publications

Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome.
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome.
Journal: Science translational medicine
Published: April 01, 2026

Frequently Asked Questions about Yang R. Liang

Is Yang R. Liang a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Yang R. Liang is classified as an Advanced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yang R. Liang participate in research or clinical trials?

Yes. Yang R. Liang has published 110 articles and abstracts on conditions like Leukemia. You can view a list of Yang R. Liang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Liang's expertise for a condition
ConditionClose
      View All 28 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile